SCHEMBL20179133

SCHEMBL20179133

CCOC(=O)c1ccc(CC(CCC(=O)NOCc2oc(=O)oc2C)C(=O)O)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.82
HTT P42858 2/20 0.39
TSHR P16473 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ESR1 P03372 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
ESR2 Q92731 1/20 0.35
CA14 Q9ULX7 1/20 0.35
MAPT P10636 3/20 0.35
PRSS1 P07477 2/20 0.35
TMPRSS15 P98073 2/20 0.35
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20179142 0.94 FOLH1 (0.72) FOLH1HTTTSHRSMN1; SMN2CA12
SCHEMBL20179147 0.91 FOLH1 (1.00) FOLH1PRSS1TMPRSS15RAB9APPARG
SCHEMBL20168739 0.89 FOLH1 (0.66) FOLH1HTTTSHRKDM4EHSD17B10
SCHEMBL21577992 0.89 FOLH1 (0.65) FOLH1HTTTSHRHSD17B10SMN1; SMN2
SCHEMBL20179247 0.86 FOLH1 (0.61) FOLH1HTTTSHRKDM4EHSD17B10
SCHEMBL21578051 0.86 FOLH1 (0.75) FOLH1TSHRKDM4EHSD17B10
SCHEMBL20179256 0.86 FOLH1 (0.80) FOLH1TSHRKDM4EHSD17B10PRSS1
SCHEMBL24023410 0.85 FOLH1 (0.74) FOLH1TSHRKDM4EHSD17B10PPARG
SCHEMBL20179144 0.84 FOLH1 (0.68) FOLH1
SCHEMBL21570573 0.82 FOLH1 (0.80) FOLH1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866394-B2 Prodrugs of hydroxamate-based GCPII inhibitors THE JOHNS HOPKINS UNIVERSTY (US) 2024-01-09 US disclosed
WO-2023154939-A2 GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING THE JOHNS HOPKINS UNIVERSITY (US) 2023-08-17 WO disclosed
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2021-11-18 US disclosed
US-11059775-B2 Prodrug compositions and utility of hydroxamate-based GCPII inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-13 US disclosed
US-20190352255-A1 NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2019-11-21 US disclosed
WO-2018094334-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352255-A1 NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS GPI, TPI1, HPGDS FOLH1 10/4885HTT 2038/4885TSHR 3946/4885
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS TPI1, HPGDS, GPI FOLH1 39/4885HTT 1518/4885TSHR 3165/4885
US-11059775-B2 Prodrug compositions and utility of hydroxamate-based GCPII inhibitors GLS, HPGDS, GPI FOLH1 15/4885HTT 2017/4885TSHR 3333/4885
US-11866394-B2 Prodrugs of hydroxamate-based GCPII inhibitors TPI1, HPGDS, GPI FOLH1 39/4885HTT 1518/4885TSHR 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.